Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Evaluating the therapeutic effectiveness of omalizumab in patients with poor-controlled asthma

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: LI, Chang-Yi (Antai Medical Care Corporation Antai Tian-Sheng Memorial hospital Pharmacy Department)
  • Co-author(s): Chang-Yi LI: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Yu-Zi ZHENG: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Bo-Wei HUANG: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Hsiang-Yu CHEN: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Li-Chen CHAN: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Chi-Cheng LIN: Department of Thoracic, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
  • Abstract:

    Background

    Asthma is an inflammatory disorder of respiratory tract, which has been defined as a chronic disease by WHO. Based on countless researches, several medical associations worldwide have published respective therapeutic instructions of asthma and kept updating annually, such as the well-known GINA guideline. As time goes by, numerous..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses